Medical professionals are raising concerns about significant disparities in approval rates of the 'rare diseases drug prior authorization system,' which differ by patients and by diseases, and the ambiguity of the criteria. The government appears to be failing to provide a direction for system improvement and address these concerns.

However, the government also agreed that significant disparities do exsit in the approval rates of prior authorization by diseases and by medical institutions. Thus, it has expressed plans to improve the approval rate through case-by-case feedback.

On 11th, Oh Chang-hyun, Director of Pharmaceutical Benefits at the Ministry of Health and Welfare, spoke at the